Castle Biosciences (CSTL) executive compensation, 2026 proxy

Derek J. Maetzold, President and CEO, was paid $6.8M in 2025, down 2% from $6.9M the year before. The CEO-to-median-employee pay ratio was 52:1, on median employee pay of $130,759.

Filed
April 8, 2026
Annual meeting
May 28, 2026
Pay year
2025
Named executives
4
CEO total pay
$6.8M-2% vs prior year
CEO to median employee
52:1median $130,759
CEO pay in equity
73%$5M in awards
Prior say-on-pay support
94%of votes cast
2025 Revenue
$344MExceeded full-year revenue guidance
CEO Pay Ratio
52:1Compared to median employee
Say-on-Pay Support
94%At 2025 annual meeting
Core Test Volume Growth
37%Year-over-year increase

How Maetzold was paid

$6.8M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary11%Stock awards73%Non-equity incentive15%All other compensation0%

Named executive officers

ExecutiveTotal
Derek J. MaetzoldPresident and CEO$6,786,771
Frank StokesChief Financial Officer$2,419,837
Tobin W. JuvenalChief Commercial Officer$2,362,571
Kristen M. OelschlagerChief Operating Officer$2,362,571

What changed and why

  • $6.8MDerek J. Maetzold received total compensation of $6,786,771 in 2025, compared to $6,941,074 in 2024.
  • $344MCastle delivered strong 2025 performance, exceeding full-year revenue guidance with approximately $344 million in revenue.
  • 94%Stockholders showed strong support for executive compensation, with approximately 94% of votes cast approving the say-on-pay proposal in 2025.
  • 50%Long-term equity incentives continued to utilize performance stock units representing 50% of the CEO total target equity value.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.